venlafaxine ER 75 mg/day (fixed dose)

Phase 3

MYLAN (VTRS)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

11 competitors in Major Depressive Disorder

AXSMAXS-05 (dextromethorphan and bupropion) oral tablets

Phase 3

PFEDVS-233 SR (desvenlafaxine sustained release )

Phase 3

View Full Landscape

Drug Information

Target Indication

Major Depressive Disorder

Clinical Trial

NCT01441440

Last updated: 12/17/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

VTRS

MYLAN

Healthcare•North America•NASDAQ

Related Pipeline

7 valent pneumococcal conjugate vaccinePhase 3

Pneumococcal Infections

EnzalutamidePhase 3

Advanced, Androgen Receptor Positive Triple Negative Breast Cancer

RSVpreFPhase 3

RESPIRATORY SYNCYTIAL VIRUS (RSV)

PF-07220060Phase 3

Breast Cancer

13-valent pneumococcal conjugate vaccine (13vPnC)Phase 3

Invasive Pneumococcal Disease

View full pipeline